Novartis India, a Rs.800 crore plus MNC, has suffered set back during the second quarter ended September 2012 and its net profit as well as EBDITA moved down. Its net profit declined by 8.9 per cent to Rs.39.34 crore from Rs.43.18 crore and EBDITA by 10.3 per cent to Rs.59.16 crore from Rs.65.90 crore in the corresponding period of last year.

The company's net sales improved only by 8.4 per cent to Rs.237.43 crore from Rs.218.97 crore. The pharmaceutical sales increased to Rs.168.54 crore during the second quarter ended September 2012 from Rs.151.20 crore, a growth of 11.5 per cent. Its generic sales improved by 4.9 per cent to Rs.14.84 crore from Rs.14.15 crore and that of OTC products declined to Rs.28.37 crore from Rs.32.54 crore. Animal Health division registered sales of Rs.25.68 crore as against Rs.21.09 crore.

For the first six months ended September 2012, Novartis' net sales improved by 9 per cent to Rs.456.95 crore. Its net profit, however, declined sharply by 17.9 per cent to Rs.66.32 crore from Rs.80.75 crore. Similarly, its EBDITA moved down by 18.6 per cent to Rs.99.62 crore from Rs.122.34 crore.